These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15021929)

  • 1. [New developments in pharmacotherapy of depression].
    Rupprecht R; Baghai TC; Möller HJ
    Nervenarzt; 2004 Mar; 75(3):273-80. PubMed ID: 15021929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in pharmacological and non-pharmacological treatment options of major depression.
    Baghai TC; Möller HJ; Rupprecht R
    Curr Pharm Des; 2006; 12(4):503-15. PubMed ID: 16472142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
    Ströhle A
    Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms.
    Bschor T; Lewitzka U; Sasse J; Adli M; Köberle U; Bauer M
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S230-4. PubMed ID: 14677084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.
    Holsboer F
    J Psychiatr Res; 1999; 33(3):181-214. PubMed ID: 10367986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test.
    Künzel HE; Binder EB; Nickel T; Ising M; Fuchs B; Majer M; Pfennig A; Ernst G; Kern N; Schmid DA; Uhr M; Holsboer F; Modell S
    Neuropsychopharmacology; 2003 Dec; 28(12):2169-78. PubMed ID: 12931142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Limbic-hypothalamic-pituitary-adrenal axis in depression: literature review].
    Twardowska K; Rybakowski J
    Psychiatr Pol; 1996; 30(5):741-55. PubMed ID: 8984515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits.
    Maric NP; Adzic M
    Psychiatr Danub; 2013 Sep; 25(3):299-305. PubMed ID: 24048401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression.
    Schüle C; Baghai TC; Eser D; Rupprecht R
    Expert Rev Neurother; 2009 Jul; 9(7):1005-19. PubMed ID: 19589050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological factors and resistance to antidepressive agents].
    Puech AJ; Corruble E
    Encephale; 1995 Mar; 21 Spec No 2():17-21. PubMed ID: 7588173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antidepressant drugs on the hypothalamic-pituitary-adrenal axis activity and glucocorticoid receptor function.
    Budziszewska B
    Pol J Pharmacol; 2002; 54(4):343-9. PubMed ID: 12523487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?
    Barden N; Reul JM; Holsboer F
    Trends Neurosci; 1995 Jan; 18(1):6-11. PubMed ID: 7535490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stress hormone system is back on the map.
    Holsboer F
    Curr Psychiatry Rep; 2000 Dec; 2(6):454-6. PubMed ID: 11122996
    [No Abstract]   [Full Text] [Related]  

  • 14. Antidepressant-like effect of geniposide on chronic unpredictable mild stress-induced depressive rats by regulating the hypothalamus-pituitary-adrenal axis.
    Cai L; Li R; Tang WJ; Meng G; Hu XY; Wu TN
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1332-41. PubMed ID: 25914157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stress responsive neurohormones in depression and anxiety.
    Ströhle A; Holsboer F
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.
    Baghai TC; Volz HP; Möller HJ
    World J Biol Psychiatry; 2006; 7(4):198-222. PubMed ID: 17071541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epiphenomenal, causal, or correlational--more on the mechanism(s) of action of antidepressants.
    Shader RI; Fogelman SM; Greenblatt DJ
    J Clin Psychopharmacol; 1998 Aug; 18(4):265-7. PubMed ID: 9690690
    [No Abstract]   [Full Text] [Related]  

  • 18. Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function.
    Nikisch G
    Neuro Endocrinol Lett; 2009 Mar; 30(1):11-6. PubMed ID: 19300389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressants and serotonergic neurotransmission: an integrative review.
    Willner P
    Psychopharmacology (Berl); 1985; 85(4):387-404. PubMed ID: 2410942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.
    Pariante CM
    Ann N Y Acad Sci; 2009 Oct; 1179():144-52. PubMed ID: 19906237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.